Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
BACKGROUND
Rotavirus infection is responsible for about 500,000 deaths annually, and the disease burden is disproportionately borne by children in low-income countries. Recently the World Health Organization (WHO) has released a global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences of rotavirus vaccines in the 72 GAVI support-eligible countries.


METHODS
We synthesized population-level data from various sources (primarily from global-level databases) for the 72 countries eligible for the support by the GAVI Alliance (GAVI-eligible countries) in order to estimate the health and economic impact associated with rotavirus vaccination programs. The primary outcome measure was incremental cost (in 2005 international dollars [I$]) per disability-adjusted life year (DALY) averted. We also projected the expected reduction in rotavirus disease burden and financial resources required associated with a variety of scale-up scenarios.


RESULTS
Under the base-case assumptions (70% coverage), vaccinating one single birth cohort would prevent about 55% of rotavirus associated deaths in the 72 GAVI-eligible countries. Assuming I$25 per vaccinated child (approximately $5 per dose), the number of countries with the incremental cost per DALY averted less than I$200 was 47. Using the WHO's cost-effectiveness threshold based on per capita GDP, the vaccines were considered cost-effective in 68 of the 72 countries (approximately 94%). A 10-year routine rotavirus vaccination would prevent 0.9-2.8 million rotavirus associated deaths among children under age 5 in the poorest parts of the world, depending on vaccine scale-up scenarios. Over the same intervention period, rotavirus vaccination programs would also prevent 4.5-13.3 million estimated cases of hospitalization and 41-107 million cases of outpatient clinic visits in the same population.


CONCLUSIONS
Our findings suggest that rotavirus vaccination would be considered a worthwhile investment for improving general development as well as childhood health level in most low-income countries, with a favorable cost-effectiveness profile even under a vaccine price ($1.5-$5.0 per dose) higher than those of traditional childhood vaccines.
Kim
Sun-Young
SY
Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA. sykim@hsph.harvard.edu
Sweet
Steve
S
Slichter
David
D
Goldie
Sue J
SJ
D003362:Cost-Benefit Analysis; D003906:Developing Countries; D005102:Health Expenditures; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D011159:Population Surveillance; D019057:Quality-Adjusted Life Years; D012400:Rotavirus Infections / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics*
D022243:Rotavirus Vaccines
Med Decis Making. 2010 Sep-Oct;30(5):E1-E28
20729510
Wkly Epidemiol Rec. 2008 Nov 21;83(47):421-5
19024780
Value Health. 2008 Dec;11(7):1081-7
19602214
J Infect Dis. 2005 Nov 15;192(10):1720-6
16235169
Bull World Health Organ. 2008 Jan;86(1):27-39
18235887
Vaccine. 2007 Dec 17;25(52):8851-60
18022735
Pharmacoeconomics. 2008;26(3):191-215
18282015
BMC Infect Dis. 2008 Jul 29;8:103
18664280
Rev Panam Salud Publica. 2008 Apr;23(4):221-30
18505602
Vaccine. 2009 Jun 19;27(30):4025-30
19389452
J Infect Dis. 2009 Nov 1;200 Suppl 1:S9-S15
19817620
J Infect Dis. 2009 Nov 1;200 Suppl 1:S195-202
19817600
J Virol. 2006 Nov;80(21):10724-33
16928744
Med Decis Making. 2007 Mar-Apr;27(2):128-37
17409363
Emerg Infect Dis. 2003 May;9(5):565-72
12737740
Educ Health (Abingdon). 2003 Jul;16(2):230
14741909
Pediatr Ann. 2006 Jan;35(1):23-8
16466072
J Infect Dis. 2005 Sep 1;192 Suppl 1:S133-45
16088797
Lancet. 2008 Apr 5;371(9619):1181-9
18395579
Rev Panam Salud Publica. 2009 Jun;25(6):481-90
19695142
J Infect Dis. 2009 Nov 1;200 Suppl 1:S114-24
19817591
J Infect Dis. 2009 Nov 1;200 Suppl 1:S28-38
19817610
Rev Panam Salud Publica. 2007 Apr;21(4):205-16
17612464
Rev Med Virol. 2005 Jan-Feb;15(1):29-56
15484186
Science. 2009 Jul 17;325(5938):290-4
19608910
Vaccine. 2007 May 16;25(20):3971-9
17400341
Vaccine. 2009 Oct 19;27(44):6121-8
19715781
Cost Eff Resour Alloc. 2006 Aug 21;4:14
16923181
N Engl J Med. 2006 Jan 5;354(1):11-22
16394298
Pharmacoeconomics. 2008;26(6):477-95
18489199
Vaccine. 2008 Jul 29;26(32):4080-93
18550229
Vaccine. 2007 Apr 20;25(16):3137-41
17321017
N Engl J Med. 2009 Nov 12;361(20):1919-21
19907040
Health Policy Plan. 2007 May;22(3):178-85
17412742
J Infect Dis. 2009 Nov 1;200 Suppl 1:S85-91
19817619
J Health Popul Nutr. 2008 Dec;26(4):388-96
19069617
J Infect Dis. 2009 Nov 1;200 Suppl 1:S76-84
19817618
J Infect Dis. 2009 Nov 1;200 Suppl 1:S70-5
19817617
Vaccine. 2007 Jan 4;25(2):373-80
16930784
BMJ. 2009 Sep 25;339:b3653
19783581
J Infect Dis. 2009 Nov 1;200 Suppl 1:S92-8
19817621
J Med Virol. 2007 Jul;79(7):1009-16
17516525
Vaccine. 2008 Jan 30;26(5):706-15
18166250
Value Health. 2007 Sep-Oct;10(5):336-47
17888098
Pediatrics. 2007 Apr;119(4):684-97
17403839
J Infect Dis. 2009 Nov 1;200 Suppl 1:S154-9
19817594
Wkly Epidemiol Rec. 2009 Jun 5;84(23):220-36
19499606
BMC Public Health. 2009 Jan 21;9:29
19159483
Epidemiol Infect. 2008 Jan;136(1):44-55
17335631
Clin Infect Dis. 2009 Oct 15;49(8):1202-10
19739973
J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27
19817595
Bull World Health Organ. 2003;81(3):197-204
12764516